GlaxoSmithKline plc (GSK) Expected to Post Earnings of $0.64 Per Share

Wall Street brokerages expect that GlaxoSmithKline plc (NYSE:GSK) will post $0.64 earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for GlaxoSmithKline’s earnings. The highest EPS estimate is $0.72 and the lowest is $0.58. GlaxoSmithKline posted earnings of $0.65 per share in the same quarter last year, which suggests a negative year-over-year growth rate of 1.5%. The firm is expected to issue its next earnings results on Wednesday, February 14th.

On average, analysts expect that GlaxoSmithKline will report full year earnings of $2.89 per share for the current financial year, with EPS estimates ranging from $2.76 to $3.00. For the next financial year, analysts expect that the business will report earnings of $2.81 per share, with EPS estimates ranging from $2.72 to $3.01. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover GlaxoSmithKline.

A number of brokerages have recently issued reports on GSK. Argus dropped their target price on shares of GlaxoSmithKline to $40.00 and set a “buy” rating on the stock in a report on Thursday. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a report on Thursday, September 21st. UBS raised shares of GlaxoSmithKline from a “neutral” rating to a “buy” rating and upped their target price for the company from $35.04 to $35.85 in a report on Monday, November 27th. Zacks Investment Research cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Finally, Investec cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Monday, November 6th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the stock. GlaxoSmithKline currently has an average rating of “Hold” and a consensus target price of $39.71.

In related news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the stock in a transaction on Monday, November 6th. The shares were purchased at an average cost of $14.00 per share, with a total value of $5,999,994.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 10.00% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its holdings in shares of GlaxoSmithKline by 46.3% during the first quarter. Geode Capital Management LLC now owns 129,145 shares of the pharmaceutical company’s stock worth $5,444,000 after purchasing an additional 40,858 shares during the period. CIBC Asset Management Inc increased its holdings in shares of GlaxoSmithKline by 9.1% during the second quarter. CIBC Asset Management Inc now owns 90,380 shares of the pharmaceutical company’s stock worth $3,865,000 after purchasing an additional 7,570 shares during the period. Bessemer Group Inc. increased its holdings in shares of GlaxoSmithKline by 22.9% during the second quarter. Bessemer Group Inc. now owns 28,734 shares of the pharmaceutical company’s stock worth $1,239,000 after purchasing an additional 5,356 shares during the period. Stratos Wealth Partners LTD. increased its holdings in shares of GlaxoSmithKline by 7.1% during the second quarter. Stratos Wealth Partners LTD. now owns 22,453 shares of the pharmaceutical company’s stock worth $968,000 after purchasing an additional 1,482 shares during the period. Finally, Rand Wealth LLC increased its holdings in shares of GlaxoSmithKline by 8.0% during the second quarter. Rand Wealth LLC now owns 5,550 shares of the pharmaceutical company’s stock worth $239,000 after purchasing an additional 410 shares during the period. 9.83% of the stock is currently owned by hedge funds and other institutional investors.

Shares of GlaxoSmithKline (NYSE:GSK) opened at $35.32 on Friday. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96. The stock has a market cap of $86,863.92, a PE ratio of 12.52, a PEG ratio of 1.96 and a beta of 0.98. GlaxoSmithKline has a fifty-two week low of $34.72 and a fifty-two week high of $44.53.

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Shareholders of record on Friday, November 10th will be issued a $0.5037 dividend. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.49. This represents a $2.01 annualized dividend and a yield of 5.70%. The ex-dividend date of this dividend is Thursday, November 9th. GlaxoSmithKline’s dividend payout ratio is currently 163.12%.

TRADEMARK VIOLATION NOTICE: “GlaxoSmithKline plc (GSK) Expected to Post Earnings of $0.64 Per Share” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.com-unik.info/2017/12/03/glaxosmithkline-plc-gsk-expected-to-post-earnings-of-0-64-per-share.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Get a free copy of the Zacks research report on GlaxoSmithKline (GSK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GlaxoSmithKline (NYSE:GSK)

What are top analysts saying about GlaxoSmithKline plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline plc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit